Print Page | Close Window

Press Releases

Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010 | 2009
DateTitle 
12/19/11Alkermes Initiates Phase 3 Clinical Study of ALKS 9070 for Treatment of SchizophreniaPrinter Friendly Version
11/29/11Alkermes' Corporate Presentation to be Webcast at the NASDAQ OMX 27th Investor ProgramPrinter Friendly Version
11/09/11New Long-Term Data on VIVITROL® Showed Sustained Efficacy and Safety over 18 Months of TreatmentPrinter Friendly Version
11/08/11Alkermes' Corporate Presentation to be Webcast at Lazard Capital Markets 8th Annual Healthcare ConferencePrinter Friendly Version
11/03/11Alkermes plc Reports Second Quarter Fiscal 2012 Financial ResultsPrinter Friendly Version
11/01/11Alkermes' Corporate Presentation to be Webcast at 2011 Annual Credit Suisse Health Care ConferencePrinter Friendly Version
10/27/11Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2012Printer Friendly Version
10/03/11Alkermes Announces Initiation of Phase 2b Clinical Study of ALKS 37 for the Treatment of Opioid-Induced ConstipationPrinter Friendly Version
09/21/11Alkermes to Present at Jefferies 2011 Global Healthcare ConferencePrinter Friendly Version
09/19/11Alkermes plc Launches Corporate Operations in IrelandPrinter Friendly Version
09/16/11Alkermes plc and Elan Corporation plc Announce Completion of Merger Between Alkermes, Inc. and Elan Drug Technologies Printer Friendly Version
09/13/11Analyses Find Type 2 Diabetes Patients Treated with BYDUREON(TM) Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011Printer Friendly Version
09/08/11Alkermes Announces Shareholder Vote in Favor of Merger with Elan Drug TechnologiesPrinter Friendly Version
09/07/11Alkermes' Corporate Presentation to be Webcast at Two Upcoming ConferencesPrinter Friendly Version
08/31/11Alkermes' Corporate Presentation to Be Webcast at Baird's 2011 Health Care ConferencePrinter Friendly Version
08/10/11BYDUREON™ FDA Action Date Set For January 28, 2012Printer Friendly Version
08/01/11Alkermes Reports First Quarter Fiscal 2012 Financial ResultsPrinter Friendly Version
07/28/11BYDUREON™ Reply Submitted to FDAPrinter Friendly Version
07/25/11Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2012Printer Friendly Version
07/18/11Alkermes Provides Outlook for Alkermes plc and Update on Advancing Product Portfolio at Analyst and Investor DayPrinter Friendly Version
07/11/11Alkermes to Webcast Analyst and Investor DayPrinter Friendly Version
07/07/11Exenatide tQT Study Showed No Prolongation of QT IntervalPrinter Friendly Version
07/07/11Alkermes Announces Results from Phase 2 Study of ALKS 33 for Treatment of Binge Eating DisorderPrinter Friendly Version
06/30/11Alkermes Announces Positive Results from Clinical Study of ALKS 9070 For Treatment of SchizophreniaPrinter Friendly Version
06/27/11Pharmacoeconomic Value of Addiction Treatments, Including VIVITROL®, Published in Leading Healthcare Policy JournalPrinter Friendly Version
06/24/11Studies Show Effect of BYDUREON™ on A1C and Weight for Up to Three YearsPrinter Friendly Version
06/24/11Once-Monthly Exenatide Improved Glucose Control in Patients with Type 2 Diabetes: Phase 2 Study Results Presented at ADA 2011Printer Friendly Version
06/24/11Analysis Shows BYDUREON(TM) Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011Printer Friendly Version
06/21/11BYDUREON™ Receives Marketing Authorization in Europe Printer Friendly Version
06/15/11Alkermes Initiates Clinical Study of ALKS 5461 for Treatment-Resistant DepressionPrinter Friendly Version
06/14/11Alkermes' Corporate Presentation to be Webcast at the NASDAQ OMX 26th Investor ProgramPrinter Friendly Version
05/31/11Alkermes' Corporate Presentation to Be Webcast at Two Upcoming ConferencesPrinter Friendly Version
05/18/11Alkermes Reports Financial Results for Fiscal 2011 and Provides Financial Expectations for Fiscal 2012Printer Friendly Version
05/17/11Alkermes' Corporate Presentation to be Webcast at the UBS Global Specialty Pharmaceuticals ConferencePrinter Friendly Version
05/11/11Alkermes to Host Conference Call to Discuss Fiscal Year 2011 Financial ResultsPrinter Friendly Version
05/09/11Alkermes Presents Phase 2 Data of ALKS 37 in Late-Breaking Oral Session at Digestive Disease Week MeetingPrinter Friendly Version
05/09/11Alkermes to Merge with Elan Drug Technologies to Create Alkermes plcPrinter Friendly Version
05/03/11Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care ConferencePrinter Friendly Version
04/27/11Data on VIVITROL®, the New FDA-Approved Medication for Prevention of Relapse to Opioid Dependence, Published in The LancetPrinter Friendly Version
04/15/11BYDUREON(TM) Recommended for Approval in EuropePrinter Friendly Version
04/11/11VIVITROL® to be Featured in Data Presentations at American Society of Addiction Medicine ConferencePrinter Friendly Version
03/10/11Exenatide Once Monthly Showed Positive Results in Phase 2 StudyPrinter Friendly Version
03/03/11DURATION-6 Top-Line Study Results AnnouncedPrinter Friendly Version
02/28/11Alkermes' Corporate Presentation to Be Webcast at the Cowen Health Care ConferencePrinter Friendly Version
02/15/11Alkermes Announces Positive Preliminary Results from Phase 2 Study of ALKS 37 for Treatment of Opioid-Induced Bowel DysfunctionPrinter Friendly Version
02/08/11Alkermes' Corporate Presentation to be Webcast at the BIO CEO & Investor ConferencePrinter Friendly Version
02/03/11Alkermes Reports Third Quarter Fiscal 2011 Financial ResultsPrinter Friendly Version
01/27/11Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2011Printer Friendly Version
01/18/11Alkermes Elects Wendy L. Dixon, Ph.D., to Board of DirectorsPrinter Friendly Version
01/07/11Alkermes Provides Update on Advancing Product Portfolio and Outlines Business Goals for 2011Printer Friendly Version
01/04/11Alkermes' Corporate Presentation to be Webcast at the JPMorgan Healthcare ConferencePrinter Friendly Version